Private Advisor Group LLC Purchases 412 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Private Advisor Group LLC lifted its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 1.8% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 22,753 shares of the biopharmaceutical company’s stock after purchasing an additional 412 shares during the quarter. Private Advisor Group LLC’s holdings in Halozyme Therapeutics were worth $1,191,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. Kornitzer Capital Management Inc. KS increased its stake in Halozyme Therapeutics by 7.7% during the second quarter. Kornitzer Capital Management Inc. KS now owns 522,734 shares of the biopharmaceutical company’s stock worth $27,370,000 after acquiring an additional 37,500 shares during the last quarter. Chase Investment Counsel Corp bought a new stake in Halozyme Therapeutics during the second quarter worth approximately $5,182,000. Hodges Capital Management Inc. increased its stake in Halozyme Therapeutics by 6.9% during the second quarter. Hodges Capital Management Inc. now owns 338,856 shares of the biopharmaceutical company’s stock worth $17,742,000 after acquiring an additional 21,811 shares during the last quarter. Convergence Investment Partners LLC bought a new stake in Halozyme Therapeutics during the second quarter worth approximately $1,374,000. Finally, Natixis Advisors LLC increased its stake in Halozyme Therapeutics by 22.1% during the second quarter. Natixis Advisors LLC now owns 65,099 shares of the biopharmaceutical company’s stock worth $3,409,000 after acquiring an additional 11,763 shares during the last quarter. 97.79% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several brokerages have weighed in on HALO. Piper Sandler cut Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and boosted their price objective for the stock from $48.00 to $51.00 in a research note on Friday, June 7th. Wells Fargo & Company boosted their price objective on Halozyme Therapeutics from $48.00 to $58.00 and gave the stock an “overweight” rating in a research note on Friday, June 7th. The Goldman Sachs Group boosted their target price on Halozyme Therapeutics from $44.00 to $49.00 and gave the company a “neutral” rating in a research report on Monday, July 22nd. JPMorgan Chase & Co. dropped their target price on Halozyme Therapeutics from $53.00 to $52.00 and set an “overweight” rating for the company in a research report on Tuesday, August 6th. Finally, Morgan Stanley boosted their target price on Halozyme Therapeutics from $59.00 to $64.00 and gave the company an “overweight” rating in a research report on Wednesday, August 7th. Two equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $59.44.

Halozyme Therapeutics Stock Up 2.9 %

Shares of NASDAQ HALO opened at $62.30 on Monday. The company has a debt-to-equity ratio of 5.19, a quick ratio of 6.21 and a current ratio of 7.41. The firm has a market capitalization of $7.89 billion, a price-to-earnings ratio of 25.74, a PEG ratio of 0.57 and a beta of 1.28. The stock has a 50 day moving average price of $57.57 and a 200 day moving average price of $48.48. Halozyme Therapeutics, Inc. has a 52-week low of $32.83 and a 52-week high of $65.53.

Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings results on Tuesday, August 6th. The biopharmaceutical company reported $0.91 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.73 by $0.18. The firm had revenue of $231.40 million during the quarter, compared to analyst estimates of $204.94 million. Halozyme Therapeutics had a return on equity of 195.80% and a net margin of 38.62%. Halozyme Therapeutics’s quarterly revenue was up 4.7% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.68 earnings per share. Sell-side analysts expect that Halozyme Therapeutics, Inc. will post 3.7 earnings per share for the current year.

Insiders Place Their Bets

In other Halozyme Therapeutics news, CEO Helen Torley sold 10,000 shares of the company’s stock in a transaction on Tuesday, September 10th. The stock was sold at an average price of $59.09, for a total transaction of $590,900.00. Following the completion of the sale, the chief executive officer now owns 676,744 shares in the company, valued at $39,988,802.96. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In other Halozyme Therapeutics news, CEO Helen Torley sold 10,000 shares of the company’s stock in a transaction on Tuesday, September 10th. The stock was sold at an average price of $59.09, for a total transaction of $590,900.00. Following the completion of the sale, the chief executive officer now owns 676,744 shares in the company, valued at $39,988,802.96. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Matthew L. Posard sold 9,881 shares of the company’s stock in a transaction on Wednesday, August 14th. The stock was sold at an average price of $57.70, for a total value of $570,133.70. Following the sale, the director now owns 69,874 shares of the company’s stock, valued at approximately $4,031,729.80. The disclosure for this sale can be found here. Insiders sold a total of 74,881 shares of company stock worth $4,267,884 over the last 90 days. Company insiders own 2.40% of the company’s stock.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.